Nissha : Financial Results (Summary) (FY 2025.12)

February 12, 2026

Company name: Nissha Co., Ltd.

Stock exchange listing: Tokyo Stock Exchange Code number: 7915

URL: https://www.nissha.com/english

Representative: Junya Suzuki, Chairman of the Board and Group CEO

Contact: Daisuke Inoue, Director of the Board, Senior Executive Vice President, Interim CFO Phone: +81-75-811-8111

Scheduled date of the Ordinary General Meeting of Shareholders: March 24, 2026 Scheduled date of commencing dividend payments: March 4, 2026

Scheduled date of filing annual securities report: March 23, 2026

Availability of supplementary briefing material on financial results: Available Schedule of financial results briefing session: Scheduled (for institutional investors)

(Amounts of less than one million yen are rounded down)

1. Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 (January 1, 2025 to December 31, 2025)

   1. Consolidated Operating Results (% indicates changes from the previous corresponding period)

      	Net sales		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Total comprehensive income
      Fiscal year ended December 31, 2025 Fiscal year ended December 31, 2024	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
      	194,898 195,598	(0.4) 16.6	4,040 5,457	(26.0) -	3,551 6,202	(42.7) -	1,383 4,011	(65.5) -	1,001 3,851	(74.0) -	4,831 11,795	(59.0) 223.4

      	Basic earnings per share	Diluted earnings per share	Ratio of return on equity attributable to owners of parent	Ratio of profit before tax to total assets	Ratio of operating profit to net sales
      Fiscal year ended December 31, 2025 Fiscal year ended December 31, 2024	Yen	Yen	%	%	%
      	21.13 79.93	- -	0.9 3.4	1.4 2.6	2.1 2.8

      (Reference) Share of profit (loss) of investments accounted for using equity method Fiscal year ended December 31, 2025: ¥(358) million

      Fiscal year ended December 31, 2024: ¥(331) million

      (Note) The Company finalized the provisional accounting treatment pertaining to business combination in the fiscal year ended December 31, 2025, and reflected the details of the finalization of the provisional accounting treatment on figures related to the fiscal year ended December 31, 2024.

   2. Consolidated Financial Position

      	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets	Equity per share attributable to owners of parent
      	Million yen	Million yen	Million yen	%	Yen
      As of December 31, 2025	250,120	117,872	115,316	46.1	2,433.56
      As of December 31, 2024	251,847	115,783	114,297	45.4	2,394.01

      (Note) The Company finalized the provisional accounting treatment pertaining to business combination in the fiscal year ended December 31, 2025, and reflected the details of the finalization of the provisional accounting treatment on figures related to the fiscal year ended December 31, 2024.

   3. Consolidated Cash Flows

      	Net cash provided by (used in) operating activities	Net cash provided by (used in) investing activities	Net cash provided by (used in) financing activities	Cash and cash equivalents at end of period
      Fiscal year ended December 31, 2025 Fiscal year ended December 31, 2024	Million yen 10,337 12,312	Million yen (13,848) (11,431)	Million yen (8,366) 9,147	Million yen 39,213 50,970

2. Dividends

   	Annual dividends					Total dividends	Payout ratio (consolidated)	Ratio of dividends to equity attributable to owners of parent (consolidated)
   	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
   Fiscal year ended December 31, 2024 Fiscal year ended December 31, 2025	Yen - -	Yen 25.00 25.00	Yen - -	Yen 25.00 25.00	Yen 50.00 50.00	Million yen 2,420 2,393	% 62.6 236.6	% 2.1 2.1
   Fiscal year ending December 31, 2026 (Forecast)	-	25.00	-	25.00	50.00		103.0

3. Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2026 (January 1, 2026 to December 31, 2026)

(% indicates changes from the previous corresponding period)

The provisional accounting treatment pertaining to Isometric Intermediate LLC and its group companies, which were acquired on March 1, 2024, Cathtek, LLC, which was acquired on October 1, 2024, as well as SHIGAKEN PHARM. IND. CO., LTD., which was acquired on January 8, 2025, was finalized during the fiscal year ended December 31, 2025. Accordingly, revised figures based on the finalization of the provisional accounting treatment have been used for the comparative analysis with figures for the previous fiscal year.

The Group's Mission is to use the diverse capabilities of its people and core technologies as an engine for growth to create highly competitive, feature-rich products and services that realize customer value and contribute to better lives for all.

Guided by this Mission, we established our Sustainability Vision as our long-term vision for 2030, and aim to create economic and social value by contributing to solving global social issues in the priority markets of Medical, Mobility, and Sustainable Materials, with the integration and orchestration of the diverse talents of our people and our technologies. Correspondingly, we have formulated and implemented the 8th Medium-term Business Plan that sets forth the medium-term plan to be achieved in the three years from fiscal 2024 to 2026 and a strategy to get there, reflecting backwards the Sustainability Vision. Aiming to achieve stable growth and increased capital efficiency, we will improve and stabilize profitability by strengthening the business portfolio we have built up to date.

During the fiscal year ended December 31, 2025, the global economy experienced restrained economic activity due to disruptions caused by the U.S. tariff policies and heightened geopolitical risks; however, the economy showed a gradual recovery. In the United States, inflation and a softening labor market dampened consumer sentiment, slowing the pace of economic expansion. In Europe, while some stagnation was observed, the economy trended toward recovery amid easing inflationary pressures and gradual interest rate cuts. In China, despite the implementation of measures to promote replacement purchases of durable consumer goods, the stagnant real estate market led to continued weakness in the economy. Meanwhile, in Japan, although the impact of the U.S. tariff policies was observed mainly in the automotive industry, the economy trended toward a moderate recovery.

Under these conditions, during the fiscal year ended December 31, 2025, product demand remained firm in the Industrial Materials and the Medical Technologies segments. On the other hand, in the Devices segment, product demand for tablets declined compared to the previous fiscal year, when demand grew due to new product launches. The contract design/development and manufacturing organization (CDMO) of over-the-counter (OTC) drugs that we have recently been focusing on have seen increased demand due to the effects of the corporate acquisition. As for profit, profitability was also pressured by upfront expenses for future growth, including the production start-up of new products for mobility components in the Industrial Materials segment and the impairment losses of existing facilities to expand production capacity in the CDMO business for OTC drugs.

As a result, regarding the financial results for the fiscal year ended December 31, 2025, net sales were ¥194,898 million (a decrease of 0.4% as compared to the previous year), operating profit was ¥4,040 million (a decrease of 26.0% as compared to the previous year) and profit attributable to owners of parent was ¥1,001 million (a decrease of 74.0% as compared to the previous year).

Following is an overview by business segment.

Industrial Materials

In the Industrial Materials segment, we mainly offer proprietary technologies that enable the creation of added value on the surfaces of various materials. IMD, IML, and IME, which facilitate simultaneous in-mold decoration, design and function

adding of plastic products, are extensively used in mobility components and home appliances in global markets. Also, the metallized paper, which unites the properties of metallic luster and printing friendliness, has the largest market share in the industry as sustainable materials for beverages and foods on a global basis.

During the fiscal year ended December 31, 2025, demand for mobility components in the fields of decorations remained firm, while demand for home appliances and other applications stayed solid, resulting in an increase in net sales year on year. On the other hand, operating profit decreased year on year mainly due to upfront expenses associated with new products for mobility components.

As a result, segment sales for the fiscal year ended December 31, 2025 were ¥76,315 million (an increase of 3.0% as compared to the previous year). Segment profit (operating profit) was ¥3,741 million (a decrease of 23.2% as compared to the previous year).

Devices

In the Devices segment, we produce components and module products that pursue precision and functionality. Our main products, film-based Touch Sensors are widely adopted mainly in tablets, handheld terminals (logistics related), mobility components, and gaming devices in global markets. In addition, we offer gas sensors that can detect gas conditions, along with other products.

During the fiscal year ended December 31, 2025, demand for tablets declined, resulting in a year-on-year decrease in net sales. However, operating profit increased year on year due to improved efficiency and productivity, reflecting pre-emptive measures, including the production restructuring.

As a result, segment sales for the fiscal year ended December 31, 2025 were ¥58,452 million (a decrease of 13.5% as compared to the previous year). Segment profit (operating profit) was ¥2,130 million (an increase of 18.5% as compared to the previous year).

Medical Technologies

The Medical Technologies segment is a business segment that offers high-quality and value-added products in medical devices and other related markets to contribute to healthy and affluent life. The segment currently provides contract design/development manufacturing services for major medical device manufacturers, especially for those in North America and Europe, with products such as surgical instruments for minimal invasive medical treatments and medical wearable sensors used for a wide range of therapeutic areas. In addition to these, the segment manufactures and sells its own brand products to medical institutions.

During the fiscal year ended December 31, 2025, net sales increased year on year, despite a partial stagnation in demand for our mainstay contract design/development manufacturing services for medical devices. On the other hand, operating profit decreased year on year, mainly due to a deterioration in the product mix of our own brand medical devices, among other factors.

As a result, segment sales for the fiscal year ended December 31, 2025 were ¥47,130 million (an increase of 3.3% as compared to the previous year). Segment profit (operating profit) was ¥2,035 million (a decrease of 14.8% as compared to the previous year).